Burning Rock Biotech Limited（BNR）の株式分析BNRBurning Rock Biotech Limited

Burning Rock Biotech Ltd is a Company principally engaged in developing and providing cancer therapy selection tests. The Company operates three businesses, including central laboratory business, in-hospital business and pharma research and development services. Central laboratory business mainly includes the sales of its cancer therapy selection test to individual patient customers. In-hospital business includes the manufacture and sales of reagent kits, as well as the provision of facilitation services for laboratory equipment sold to hospitals. The pharma research and development services include a range of cancer therapy selection test services, analytical validation services and project management services. It operates in the Healthcare sector (MEDICAL LABORATORIES industry).

Burning Rock Biotech Ltd (BNR) appears to be a good buy right now due to its recent upward price movement of 4.19% over the last five days and a current price of $10.19, which is close to its Fibonacci resistance level of $10.63. The stock's RSI of 57.18 indicates that it is not overbought, suggesting room for further growth. However, the main risk is its declining revenue trend, with a 14.7% year-over-year decrease in Q1 2026, which could impact future profitability.